Omachi K, Kamura M, Teramoto K, Kojima H, Yokota T, Kaseda S, Kuwazuru J, Fukuda R, Koyama K, Matsuyama S, Motomura K, Shuto T, Suico MA, Kai H.
A split-luciferase-based trimer formation assay as a high-throughput screening platform for therapeutics in Alport syndrome.
Cell Chem Biol.2018 May 17;25(5):634-643.e4. doi:10.1016/j.chembiol.2018.02.003.

Yokota T, Omachi K, Suico MA, Kamura M, Kojima H, Fukuda R, Motomura K, Teramoto K, Kaseda S, Kuwazuru J, Takeo T, Nakagata N, Shuto T, Kai H.
STAT3 inhibition attenuates the progressive phenotypes of Alport syndrome mouse model.
Nephrol Dial Transplant. 2018 Feb 1;33(2):214-223. doi: 10.1093/ndt/gfx246.

Kamei S, Fujikawa H, Nohara H, Ueno-Shuto K, Maruta K, Nakashima R, Kawakami T, Matsumoto C, Sakaguchi Y, Ono T, Suico MA, Boucher RC, Gruenert DC, Takeo T, Nakagata N, Li JD, Kai H, Shuto T.
Zinc Deficiency via a Splice Switch in Zinc Importer ZIP2/SLC39A2 Causes Cystic Fibrosis-Associated MUC5AC Hypersecretion in Airway Epithelial Cells.
EBioMedicine. 2018 Jan;27:304-316. doi: 10.1016/j.ebiom.2017.12.025.

Wakita Y, Sato T, Chosa K, Suico MA, Sasaki R, Kawano S, Hashimoto N, Teranishi Y, Imai Y, Morioka H, Shuto T, Kai H.
Characterization of non-amyloidogenic G101S transthyretin, Biological and Pharmaceutical Bulletin
Biol Pharm Bull. 2018;41(4):628-636. doi: 10.1248/bpb.b17-01021.

Yokota T, Omachi K, Suico MA, Kojima H, Kamura M, Teramoto K, Kaseda S, Kuwazuru J, Shuto T, Kai H.
Bromide supplementation exacerbated the renal dysfunction, injury and fibrosis in a mouse model of Alport syndrome.
PLoS One. 2017 Sep 5;12(9):e0183959. doi: 10.1371/journal.pone.0183959. eCollection 2017.

Koga T, Shiraki N, Yano S, Suico MA, Morino-Koga S, Sato T, Shuto T, Kume S, Kai H.
Mild electrical stimulation with heat shock guides differentiation of embryonic stem cells into Pdx1-expressing cells within the definitive endoderm.
BMC Biotechnol. 2017 Feb 15;17(1):14. doi: 10.1186/s12896-017-0331-z.

Omachi K, Miyakita R, Fukuda R, Kai Y, Suico MA, Yokota T, Kamura M, Shuto T, Kai H.
Long-term treatment with EGFR inhibitor erlotinib attenuates renal inflammatory cytokines but not nephropathy in Alport syndrome mouse model.
Clin Exp Nephrol. 2017 Feb 8. doi: 10.1007/s10157-017-1386-9

Suico MA, Shuto T, Kai H.
Roles and regulations of the ETS transcription factor ELF4/MEF.
J Mol Cell Biol.2017 Jun 1;9(3):168-177. doi: 10.1093/jmcb/mjw051.